Headquartered
in Dublin, Ireland, Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical
company whose aim is to improve lives with the recognition, development,
acquisition, and commercialization of accessible medicines to meet a variety of
patient medical needs. Horizon Pharma now markets nine key products through its
orphan, rheumatology, and primary care business units.
Products
include ACTIMMUNE®, Buphenyl®, Duexis®, KRYSTEXXA®, Migergot®, PENNSAID® 2%,
Ravicti®, Rayos®, and Vimovo®. These products are used to reduce the frequency
and severity of serious infections, treat patients with urea cycle disorders,
relieve signs and symptoms of rheumatoid arthritis and osteoarthritis, decrease
the risk of developing upper gastrointestinal ulcers, and treat patients with
chronic gout, among other symptoms and diseases.
In
October 2014, HZNP acquired PENNSAID® 2%, followed by Hyperion Therapeutics in
May 2015. At the beginning of this year, the company completed the acquisition
of Crealta Holdings LLC, which allowed it to expand its orphan business with KRYSTEXXA®
(pegloticase), a biologic medicine for chronic, refractory gout.
In
addition, Horizon Pharma recently entered into a definitive agreement with
Raptor Pharmaceutical Corp. (NASDAQ: RPTP), through which HZNP will acquire all
of the issued and outstanding shares of RPTP common stock for a cash payment of
$9.00 per share. The transaction is expected to be completed by the end of 2016
and is estimated to be worth $800 million.
Horizon
Pharma has approximately 890 global employees and operates across Ireland,
Europe, and the United States. As of August 9, 2016, Horizon Pharma had a
market capitalization of $3.60 billion. The company has seen steady growth in
net sales and adjusted EBITDA. With net sales up from $74 million in 2013 to
over $1 billion in 2015, HZNP expects to strengthen its focus on rare diseases
while expanding further into Europe and other international markets.
For
more information, visit the company’s website at www.HorizonPharma.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
